利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

72 条记录 (耗时 0.058 秒)

    Antibodies and utilization thereof
    11.
    发明授权
    Antibodies and utilization thereof 失效
    抗体及其利用

    公开(公告)号：US07067268B1

    公开(公告)日：2006-06-27

    申请号：US09700643

    申请日：1999-05-20

    申请人： Hirokazu Matsumoto ,  Chieko Kitada ,  Shuji Hinuma

    发明人： Hirokazu Matsumoto ,  Chieko Kitada ,  Shuji Hinuma

    IPC分类号： G01N33/53

    CPC分类号： G01N33/74 ,  C07K16/18 ,  C07K16/26 ,  G01N33/6854

    摘要： The anti-19P2 ligand monoclonal antibodies of the invention (in particular P2L-1Ca) have very high binding ability and can neutralize the arachidonic acid metabolite releasing activity of the 19P2 ligand. Therefore, they can be used, among others, as diagnostic, prophylactic and/or therapeutic agents for various diseases caused by some or other abnormality in the pituitary function modulating activity (e.g. prolactin secretion promoting activity), central nervous system modulating activity and pancreatic function modulating activity, among others, supposedly possessed by the 19P2 ligand.The immunoassay method using the monoclonal antibodies of the invention by the sandwich technique (in particular the sandwich technique using the monoclonal antibody and an antibody recognizing an intermediate portion of the 19P2 ligand) can assay the 19P2 ligand or a derivative thereof specifically and with high sensitivity. This assay method can be used in elucidating the physiological functions of the 19P2 ligand or a derivative thereof.

    摘要翻译： 本发明的抗-19P2配体单克隆抗体（特别是P2L-1Ca）具有非常高的结合能力，可中和19P2配体的花生四烯酸代谢物释放活性。 因此，它们可以用作垂体功能调节活性（例如催乳素分泌促进活性），中枢神经系统调节活性和胰腺功能的一些或其他异常引起的各种疾病的诊断，预防和/或治疗剂 19P2配体据称具有调节活性。 使用本发明的单克隆抗体通过夹心技术（特别是使用单克隆抗体的夹心技术和识别19P2配体的中间部分的抗体）的免疫测定方法可以特异性且高灵敏度地测定19P2配体或其衍生物 。 该测定方法可用于阐明19P2配体或其衍生物的生理功能。

    Antiobestic agents methods for screening antiobestic agents and kits comprising same
    12.
    发明授权
    Antiobestic agents methods for screening antiobestic agents and kits comprising same 失效
    用于筛选抗生物剂的抗生物剂方法和包含其的试剂盒

    公开(公告)号：US06991908B1

    公开(公告)日：2006-01-31

    申请号：US09869540

    申请日：1999-12-27

    申请人： Masaaki Mori ,  Yukio Shimomura ,  Shiro Takekawa ,  Tsukasa Sugo ,  Yoshihiro Ishibashi ,  Chieko Kitada ,  Nobuhiro Suzuki

    发明人： Masaaki Mori ,  Yukio Shimomura ,  Shiro Takekawa ,  Tsukasa Sugo ,  Yoshihiro Ishibashi ,  Chieko Kitada ,  Nobuhiro Suzuki

    IPC分类号： G01N33/53

    CPC分类号： C07K7/08 ,  A61K38/10 ,  G01N33/74 ,  G01N2333/575 ,  G01N2333/726 ,  G01N2500/00 ,  G01N2500/02 ,  Y10S436/808

    摘要： The present invention provides a method for screening a compound or its salt that alters the binding property between MCH or its salt and SLC-1 or its salt, characterized by using MCH or its derivative or a salt thereof and SLC-1 or its salt is useful for screening an SLC-1 agonist which can be used not only as an appetite (eating) promoting agent but also as a prophylactic/therapeutic agent for weak pains, atonic bleeding, before and after expulsion, subinvolution of uterus, cesarean section, induced abortion, galactostasis, and the like, and an SLC-1 antagonist which can be used not only as an antiobestic agents (drug), an appetite (eating) modulator, and the like, but also as a prophylactic/therapeutic agent for hyperstimulation, ankylosing uterine contractions, fetal distress, uterine rupture, cervical laceration, preterm delivery, Prader-Wili syndrome and the like.

    摘要翻译： 本发明提供一种筛选化合物或其盐的方法，其改变MCH或其盐与SLC-1或其盐之间的结合性质，其特征在于使用MCH或其衍生物或其盐，SLC-1或其盐是 可用于筛选SLC-1激动剂，其不仅可以用作食欲（进食）促进剂，而且可用作弱疼痛，无症状出血，驱除前后，子宫切除，剖宫产，诱导 流产，半乳糖淀粉酶等，以及不仅可以用作抗生素（药物），食欲调节剂等的SLC-1拮抗剂，而且可以用作过度刺激的预防/治疗剂， 强直性子宫收缩，胎儿窘迫，子宫破裂，子宫颈撕裂，早产，Prader-Wili综合征等。

    Antibody and use thereof
    14.
    发明申请
    Antibody and use thereof 失效
    抗体及其用途

    公开(公告)号：US20050158795A1

    公开(公告)日：2005-07-21

    申请号：US11004336

    申请日：2004-12-03

    申请人： Hirokazu Matsumoto ,  Chieko Kitada ,  Shuji Hinuma

    发明人： Hirokazu Matsumoto ,  Chieko Kitada ,  Shuji Hinuma

    IPC分类号： C07K16/18 ,  C07K16/26 ,  C12P21/08 ,  G01N33/68 ,  G01N33/74 ,  G01N33/53

    CPC分类号： G01N33/74 ,  C07K16/18 ,  C07K16/26 ,  G01N33/6854

    摘要： The anti-19P2 ligand monoclonal antibodies of the invention (in particular P2L-1Ca) have very high binding ability and can neutralize the arachidonic acid metabolite releasing activity of the 19P2 ligand. Therefore, they can be used, among others, as diagnostic, prophylactic and/or therapeutic agents for various diseases caused by some or other abnormality in the pituitary function modulating activity (e.g. prolactin secretion promoting activity), central nervous system modulating activity and pancreatic function modulating activity, among others, supposedly possessed by the 19P2 ligand. The immunoassay method using the monoclonal antibodies of the invention by the sandwich technique (in particular the sandwich technique using the monoclonal antibody and an antibody recognizing an intermediate portion of the 19P2 ligand) can assay the 19P2 ligand or a derivative thereof specifically and with high sensitivity. This assay method can be used in elucidating the physiological functions of the 19P2 ligand or a derivative thereof.

    摘要翻译： 本发明的抗-19P2配体单克隆抗体（特别是P2L-1Ca）具有非常高的结合能力，可中和19P2配体的花生四烯酸代谢物释放活性。 因此，它们可以用作垂体功能调节活性（例如催乳素分泌促进活性），中枢神经系统调节活性和胰腺功能的一些或其他异常引起的各种疾病的诊断，预防和/或治疗剂 19P2配体据称具有调节活性。 使用本发明的单克隆抗体通过夹心技术（特别是使用单克隆抗体的夹心技术和识别19P2配体的中间部分的抗体）的免疫测定方法可以特异性且高灵敏度地测定19P2配体或其衍生物 。 该测定方法可用于阐明19P2配体或其衍生物的生理功能。

    Polypeptides, their production and use
    15.
    发明授权
    Polypeptides, their production and use 失效
    多肽，其生产和使用

    公开(公告)号：US06881545B1

    公开(公告)日：2005-04-19

    申请号：US09716147

    申请日：2000-11-17

    申请人： Shuji Hinuma ,  Yugo Habata ,  Yuji Kawamata ,  Masaki Hosoya ,  Ryo Fujii ,  Shoji Fukusumi ,  Chieko Kitada

    发明人： Shuji Hinuma ,  Yugo Habata ,  Yuji Kawamata ,  Masaki Hosoya ,  Ryo Fujii ,  Shoji Fukusumi ,  Chieko Kitada

    IPC分类号： C07K14/575 ,  C07K14/705 ,  G01N33/53 ,  C07K7/08 ,  C07K14/72

    CPC分类号： C07K14/705 ,  C07K14/575

    摘要： The present invention relates to the ligand polypeptide for the human pituitary- and mouse pancreas-derived G protein-coupled receptor proteins.The ligand polypeptide or the DNA which codes for the ligand polypeptide can be used for (1) development of medicines such as pituitary function modulators, central nervious system function modulators, and pancreatic function modulators, and (2) development of receptor binding assay systems using the expression of recombinant receptor proteins and screening of pharmaceutical candidate compounds.In particular, by the receptor binding assay systems utilizing the expression of recombinant G protein-coupled receptor proteins in accordance with the invention, agonists and antagonists of G protein-coupled receptors which are specific to human and other warm-blooded animals can be screened and the agonists or antagonists obtained can be used as therapeutic and prophylactic agents for various diseases.

    摘要翻译： 本发明涉及用于人垂体和小鼠胰腺衍生的G蛋白偶联受体蛋白质的配体多肽。 编码配体多肽的配体多肽或DNA可用于（1）开发药物，例如垂体功能调节剂，中枢神经系统功能调节剂和胰功能调节剂，以及（2）开发受体结合测定系统，其使用 重组受体蛋白的表达和药物候选化合物的筛选。 特别地，通过利用根据本发明的重组G蛋白偶联受体蛋白表达的受体结合测定系统，可以筛选对人类和其他温血动物特异性的G蛋白偶联受体的激动剂和拮抗剂， 获得的激动剂或拮抗剂可用作各种疾病的治疗和预防剂。

    PACAP receptor protein, method for preparing said protein, and use thereof
    16.
    发明授权
    PACAP receptor protein, method for preparing said protein, and use thereof 失效
    PACAP受体蛋白质，所述蛋白质的制备方法及其用途

    公开(公告)号：US06399316B1

    公开(公告)日：2002-06-04

    申请号：US09201474

    申请日：1998-11-30

    申请人： Haruo Onda ,  Tetsuya Ohtaki ,  Yasushi Masuda ,  Chieko Kitada ,  Yoshihiro Ishibashi ,  Masaki Hosoya ,  Kazuhiro Ogi ,  Yasunori Miyamoto ,  Yugo Habata ,  Norio Shimamoto

    发明人： Haruo Onda ,  Tetsuya Ohtaki ,  Yasushi Masuda ,  Chieko Kitada ,  Yoshihiro Ishibashi ,  Masaki Hosoya ,  Kazuhiro Ogi ,  Yasunori Miyamoto ,  Yugo Habata ,  Norio Shimamoto

    IPC分类号： G01N3353

    CPC分类号： C07K14/72 ,  A61K38/00 ,  A61K48/00

    摘要： This invention discloses a PACAP receptor protein or a salt thereof, a DNA comprising a DNA fragment coding for the protein, a method for preparing the protein, antibody against the protein, and use of the protein, DNA, and antibodies. A PACAP receptor protein was purified from the bovine cerebrum. DNAs coding for PACAP receptor proteins were isolated from bovine, rat and human cDNA libraries, and their nucleotide sequences were determined. Further, amino acid sequences deduced from the nucleotide sequences were determined. The PACAP receptor proteins and the DNAs coding for the proteins of the present invention can be used for (1) acquisition of antibodies and antisera, (2) construction of expression systems of recombinant receptor proteins, (3) development of receptor binding assay systems using said expression systems and screening of potential compounds for drugs, (4) execution of drug design based on the comparison of ligands and receptors which are structurally similar to each other, (5) preparation of probes and PCR primers in gene diagnosis, and the like.

    摘要翻译： 本发明公开了一种PACAP受体蛋白或其盐，包含编码该蛋白质的DNA片段的DNA，该蛋白质的制备方法，针对该蛋白质的抗体以及该蛋白质，DNA及抗体的用途。 从牛大脑中纯化PACAP受体蛋白。 从牛，大鼠和人类cDNA文库中分离编码PACAP受体蛋白的DNA，测定其核苷酸序列。 此外，确定从核苷酸序列推导的氨基酸序列。 PACAP受体蛋白和编码本发明蛋白的DNA可用于（1）获得抗体和抗血清，（2）构建重组受体蛋白质的表达系统，（3）开发受体结合测定系统，使用 表达系统和药物潜在化合物的筛选，（4）基于结构相似的配体和受体的比较来执行药物设计，（5）基因诊断中探针和PCR引物的制备等 。

    Polypeptides and use thereof
    18.
    发明授权
    Polypeptides and use thereof 失效
    多肽及其用途

    公开(公告)号：US5801147A

    公开(公告)日：1998-09-01

    申请号：US766725

    申请日：1996-12-13

    申请人： Chieko Kitada ,  Takuya Watanabe

    发明人： Chieko Kitada ,  Takuya Watanabe

    IPC分类号： A61K38/00 ,  C07K1/00 ,  C07K14/575 ,  C07K14/00

    CPC分类号： C07K1/006 ,  C07K14/57563 ,  A61K38/00

    摘要： Disclosed are (1) a polypeptide represented by formula (I), or a pharmaceutically acceptable amide, ester or salt thereof: His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-NH-CHX-CO-Ala-Val-Lys-Lys-Tyr-Y SEQ ID NO:13 (I) wherein X is hydrogen atom; or a lower alkyl group which may be substituted with a member selected from the group consisting of hydroxy group, substituted or unsubstituted amino group, carboxyl group, carbamoyl group, and substituted or unsubstituted aromatic group; and Y is one of amino acids or peptides consisting of 1 to 16 amino acid residues counted from the N-terminal side of Leu-Ala-Ala-Val-Leu-Gly-Lys-Arg-Tyr-Lys-Gln-Arg-Val-Lys-Asn-Lys SEQ ID NO:20, and (2) a pharmaceutical composition comprising a polypeptide represented by formula (I), or a pharmaceutically acceptable amide, ester or salt thereof, which has remarkable c-AMP activity and is useful as a nerve activating agent.

    摘要翻译： 公开了（1）式（I）表示的多肽或其药学上可接受的酰胺，酯或其盐：His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr -Arg-Lys-Gln-NH-CHX-CO-Ala-Val-Lys-Lys-Tyr-Y SEQ ID NO：13（I）其中X是氢原子; 或可以被选自羟基，取代或未取代的氨基，羧基，氨基甲酰基和取代或未取代的芳基的成员取代的低级烷基; Y是从Leu-Ala-Ala-Val-Leu-Gly-Lys-Arg-Tyr-Lys-Gln-Arg-Val的N-末端计数的1至16个氨基酸残基组成的氨基酸或肽之一 -Lys-Asn-Lys SEQ ID NO：20，和（2）包含由式（I）表示的多肽或其药学上可接受的酰胺，酯或其盐的药物组合物，其具有显着的c-AMP活性并且是有用的 作为神经活化剂。